Region Hovedstaden

Research site

Denmark Dyrehavevej 29, 3400 Hillerød, Denmark

13 trials recruiting
Type 2 diabetes mellitus · Obesity · Arteriosclerosis
Adults and children

About Specializations

Region Hovedstaden in Hillerød, Denmark specialises in clinical trials of conditions such as Type 2 diabetes mellitus, Obesity, Arteriosclerosis, Graves' disease, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Dyrehavevej 293400 HillerødDenmark

Open in maps ↗

Recruiting now: 13 trials
Conditions studied: 19

More sites in Hillerød Denmark

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

16 clinical trials

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Denmark

Participants:18–64 years · 65+ years
Sponsor:AstraZeneca AB

Contact Research Centre

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug

Denmark

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Contact Research Centre

Colitis ulcerative

Recruiting

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Golimumab
Sponsor:Janssen Cilag International

Contact Research Centre

Type 2 diabetes mellitus

Recruiting

A study to assess the effect of elecoglipron alone and in combination with dapagliflozin on blood sugar control in adults with Type 2 diabetes

Registered drug

A study to assess the effect of elecoglipron alone and in combination with dapagliflozin on blood sugar control in adults with Type 2 diabetes

Registered drug

Denmark

Participants:18–64 years · 65+ years
Substances:AZD5004
Sponsor:AstraZeneca AB

Contact Research Centre

Type 2 diabetes mellitus

Recruiting

Randomized trial of elecoglipron with dapagliflozin versus placebo in adults with type 2 diabetes mellitus and impaired renal function

Registered drug

Randomized trial of elecoglipron with dapagliflozin versus placebo in adults with type 2 diabetes mellitus and impaired renal function

Registered drug

Denmark

Participants:18–64 years · 65+ years
Substances:AZD5004
Sponsor:AstraZeneca AB

Contact Research Centre

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Guselkumab
Sponsor:Janssen Cilag International

Contact Research Centre

Obesity

Recruiting

Zenagamtide for Weight Loss in Adults with Obesity

Investigational

Zenagamtide for Weight Loss in Adults with Obesity

Investigational

Denmark

Participants:18–64 years · 65+ years
Sponsor:Novo Nordisk A/S

Contact Research Centre

General anaesthesia+1

Recruiting

Comparison of remifentanil and rocuronium for improving video laryngoscopy assisted tracheal intubation in adult patients undergoing general anesthesia

Registered drugNo placebo

Comparison of remifentanil and rocuronium for improving video laryngoscopy assisted tracheal intubation in adult patients undergoing general anesthesia

Registered drugNo placebo

Denmark

Participants:18–64 years
Substances:Rocuronium Bromide
Sponsor:Nordsjaellands Hospital

Contact Research Centre

Type 1 diabetes mellitus+1

Recruiting

Study of semaglutide for weight loss in adults with type 1 diabetes and obesity

Registered drugNo placebo

Study of semaglutide for weight loss in adults with type 1 diabetes and obesity

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Placebo
Sponsor:Rigshospitalet

Contact Research Centre

Caesarean section

Recruiting

Study on Pain Relief and Safety of Low-Dose Intrathecal Morphine for Women Undergoing Planned Caesarean Section

Registered drug

Study on Pain Relief and Safety of Low-Dose Intrathecal Morphine for Women Undergoing Planned Caesarean Section

Registered drug

Denmark

Participants:18–64 years
Substances:Morphine Hydrochloride
Sponsor:Region Sjaelland

Contact Research Centre

Acute myocardial infarction

Recruiting

Study Comparing Aspirin Alone to Aspirin and Fondaparinux in Patients with Non-ST-Elevation Myocardial Infarction (NSTEMI)

Registered drugNo placebo

Study Comparing Aspirin Alone to Aspirin and Fondaparinux in Patients with Non-ST-Elevation Myocardial Infarction (NSTEMI)

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Acetylsalicylic Acid
Sponsor:Region Midtjylland

Contact Research Centre

Renal failure

Recruiting

Study on Preventing Blood Infections in Hemodialysis Patients Using Amoxicillin/Clavulanic Acid or Clindamycin

Registered drugNo placebo

Study on Preventing Blood Infections in Hemodialysis Patients Using Amoxicillin/Clavulanic Acid or Clindamycin

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Amoxicillin
Sponsor:Region Sjaelland

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites